Insilico Medicine plans share buyback of up to HK$ 500 million

PUBT · 1d ago
Insilico Medicine plans share buyback of up to HK$ 500 million
  • Insilico Medicine's board announced a share repurchase program of up to HK$ 500 million on October 30, 2026.
  • Open-market purchases on Hong Kong's stock exchange will use internal financial resources, excluding global offering proceeds.
  • The program falls under the shareholder mandate granted June 2, 2026; implementation remains subject to market conditions and board discretion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insilico Medicine Cayman Topco published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261030-12388996), on October 30, 2026, and is solely responsible for the information contained therein.